Salvage bortezomib–dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial

por Gimsing, P, Hjertner, Ø, Abildgaard, N, Andersen, N F, Dahl, T G, Gregersen, H, Klausen, T W, Mellqvist, U-H, Linder, O, Lindås, R, Tøffner Clausen, N, Lenhoff, S
Publicado 2015